News

Engaging Hard-To-Target Receptors with Antibodies That Activate

Partners aim to develop new class of obesity therapeutics

GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space

Paving the road to functionally active antibody drugs

Bay Area lab utilizes AI in search for next effective weight loss drug

East Bay company aims to tame a shrew to make better GLP-1 weight-loss drugs

GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space

Interview with Richard Yu, PhD Co-Founder & CEO, Abalone Bio

The promise and challenges of functionally active GPCR antibody drugs

FAST: Enabling the rapid discovery and creation of GPCR agonist antibodies